GANX – gain therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 [Yahoo! Finance]
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential [Seeking Alpha]
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Form 10-Q Gain Therapeutics, Inc. For: Mar 31
Form 8-K Gain Therapeutics, Inc. For: May 14
Form ARS Gain Therapeutics, Inc. For: Dec 31
Form DEFA14A Gain Therapeutics, Inc.
Form DEF 14A Gain Therapeutics, Inc. For: Jun 24
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.